{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:50:29Z","timestamp":1782604229965,"version":"3.54.5"},"reference-count":51,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Liver cirrhosis and splanchnic vein thrombosis (SVT) are strictly correlated. Portal vein thrombosis, the most common location of SVT, is frequently diagnosed in liver cirrhosis (pooled incidence 4.6 per 100 patient-years), and liver cirrhosis is a common risk factor for SVT (reported in 24%-28% of SVT patients). In cirrhosis-associated SVT, anticoagulant treatment reduces mortality rates, thrombosis extension, and major bleeding, and increases the rates of recanalization, compared to no treatment. Achieving vessel recanalization improves the prognosis of cirrhotic patients by reducing liver-related complications (such as variceal bleeding, ascites, hepatic encephalopathy). Anticoagulation should be therefore routinely prescribed to cirrhotic patients with acute SVT unless contraindicated by active bleeding associated with hemodynamic impairment or by excessively high bleeding risk. Of note, early treatment is associated with higher probability of achieving vessel recanalization. The standard treatment consists of low-molecular-weight heparin, followed by oral anticoagulants (eg, vitamin K antagonists or direct oral anticoagulants), if not contraindicated by severe liver dysfunction. Cirrhotic patients with SVT should be treated long-term (especially if candidate for liver transplantation) since liver cirrhosis is a persistent risk factor for recurrent thrombosis. In this review, we discuss the management of SVT in patients with liver cirrhosis, with a focus on the anticoagulant treatment in terms of indications, timing, drugs, duration, and particular scenarios, such as gastroesophageal varices and thrombocytopenia.<\/jats:p>","DOI":"10.1182\/hematology.2023000481","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:09:19Z","timestamp":1702048159000},"page":"281-288","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":14,"title":["How to manage splanchnic vein thrombosis in patients with liver disease"],"prefix":"10.1182","volume":"2023","author":[{"given":"Nicoletta","family":"Riva","sequence":"first","affiliation":[{"name":"1 Department of Pathology, Faculty of Medicine and Surgery, University of Malta, Msida, Malta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Ageno","sequence":"additional","affiliation":[{"name":"2 Department of Medicine and Surgery, University of Insubria, Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"issue":"2","key":"2023120815060343800_hem2023000481C1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/17474086.2023.2184340","article-title":"Anticoagulant therapy for splanchnic vein thrombosis: recent updates for patients with liver cirrhosis","volume":"16","author":"Caiano","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"2023120815060343800_hem2023000481C2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejim.2022.05.032","article-title":"Epidemiology of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis","volume":"104","author":"Pan","year":"2022","journal-title":"Eur J Intern Med"},{"issue":"9","key":"2023120815060343800_hem2023000481C3","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1001\/jamainternmed.2015.3184","article-title":"Long-term clinical outcomes of splanchnic vein thrombosis: results of an international registry","volume":"175","author":"Ageno","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"2","key":"2023120815060343800_hem2023000481C4","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.cgh.2009.09.019","article-title":"Survival and recurrence in patients with splanchnic vein thromboses","volume":"8","author":"Thatipelli","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"2023120815060343800_hem2023000481C5","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.jhep.2021.07.020","article-title":"Predicting portal thrombosis in cirrhosis: a prospective study of clinical, ultrasonographic and hemostatic factors","volume":"75","author":"Turon","year":"2021","journal-title":"J Hepatol"},{"issue":"1","key":"2023120815060343800_hem2023000481C6","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/hep.31646","article-title":"Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases","volume":"73","author":"Northup","year":"2021","journal-title":"Hepatology"},{"issue":"8","key":"2023120815060343800_hem2023000481C7","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41424-018-0043-2","article-title":"Long-term outcome of splanchnic vein thrombosis in cirrhosis","volume":"9","author":"Senzolo","year":"2018","journal-title":"Clin Transl Gastroenterol"},{"issue":"3","key":"2023120815060343800_hem2023000481C8","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.gtc.2010.08.015","article-title":"Clinical pharmacology of portal hypertension","volume":"39","author":"Mi\u00f1ano","year":"2010","journal-title":"Gastroenterol Clin North Am"},{"issue":"26","key":"2023120815060343800_hem2023000481C9","first-page":"1","article-title":"Diagnosis and management of portal vein thrombosis in patients with cirrhosis of liver","volume":"6","author":"Adams","year":"2018","journal-title":"Southwest Resp Crit Care Chronicles"},{"issue":"6","key":"2023120815060343800_hem2023000481C10","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/jgh.14501","article-title":"Portal vein thrombosis prevalence and associated mortality in cirrhosis in a nationally representative inpatient cohort","volume":"34","author":"Cool","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"issue":"16","key":"2023120815060343800_hem2023000481C11","doi-asserted-by":"crossref","first-page":"e25439","DOI":"10.1097\/MD.0000000000025439","article-title":"Effect of portal vein thrombosis on the prognosis of patients with cirrhosis without a liver transplant: a systematic review and meta-analysis","volume":"100","author":"Xian","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"15","key":"2023120815060343800_hem2023000481C12","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1182\/bloodadvances.2022007961","article-title":"Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis","volume":"6","author":"Candeloro","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"2023120815060343800_hem2023000481C13","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41395-018-0421-0","article-title":"Clinical impact and safety of anticoagulants for portal vein thrombosis in cirrhosis","volume":"114","author":"Pettinari","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"2023120815060343800_hem2023000481C14","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1007\/s10620-020-06695-4","article-title":"Safety, efficacy, and long-term outcomes of anticoagulation in cirrhotic portal vein thrombosis","volume":"66","author":"Naymagon","year":"2021","journal-title":"Dig Dis Sci"},{"issue":"7","key":"2023120815060343800_hem2023000481C15","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1055\/s-0040-1722192","article-title":"Anticoagulant treatment for splanchnic vein thrombosis in liver cirrhosis: a systematic review and meta-analysis","volume":"121","author":"Valeriani","year":"2021","journal-title":"Thromb Haemost"},{"issue":"2","key":"2023120815060343800_hem2023000481C16","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1053\/j.gastro.2017.04.042","article-title":"Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis","volume":"153","author":"Loffredo","year":"2017","journal-title":"Gastroenterology"},{"issue":"1","key":"2023120815060343800_hem2023000481C17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2023.02.023","article-title":"Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: the IMPORTAL competing-risk meta-analysis","volume":"79","author":"Guerrero","year":"2023","journal-title":"J Hepatol"},{"issue":"7","key":"2023120815060343800_hem2023000481C18","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.cgh.2012.01.012","article-title":"Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis","volume":"10","author":"Delgado","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023120815060343800_hem2023000481C19","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2147\/VHRM.S310615","article-title":"Anticoagulation and vessel recanalization in cirrhotic patients with splanchnic vein thrombosis: a multidisciplinary \u201creal life\u201d experience","volume":"17","author":"Rupoli","year":"2021","journal-title":"Vasc Health Risk Manag"},{"issue":"7","key":"2023120815060343800_hem2023000481C20","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.cgh.2017.10.016","article-title":"Harmful and beneficial effects of anticoagulants in patients with cirrhosis and portal vein thrombosis","volume":"16","author":"La Mura","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023120815060343800_hem2023000481C21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2022.05.012","article-title":"Clinical predictors for thrombus progression in cirrhotic patients with untreated splanchnic vein thrombosis","volume":"216","author":"McMurry","year":"2022","journal-title":"Thromb Res"},{"issue":"1","key":"2023120815060343800_hem2023000481C22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.14309\/ajg.0000000000000486","article-title":"ACG Clinical Guideline: disorders of the hepatic and mesenteric circulation","volume":"115","author":"Simonetto","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"2023120815060343800_hem2023000481C23","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/jth.14836","article-title":"Anticoagulant therapy for splanchnic vein thrombosis: ISTH SSC Subcommittee Control of Anticoagulation","volume":"18","author":"Di Nisio","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2023120815060343800_hem2023000481C24","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - Renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"issue":"5","key":"2023120815060343800_hem2023000481C25","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1053\/j.gastro.2021.08.015","article-title":"AGA clinical practice guideline on the management of coagulation disorders in patients with cirrhosis","volume":"161","author":"O'Shea","year":"2021","journal-title":"Gastroenterology"},{"issue":"10","key":"2023120815060343800_hem2023000481C26","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1097\/MEG.0000000000001846","article-title":"Efficacy and safety study of direct-acting oral anticoagulants for the treatment of chronic portal vein thrombosis in patients with liver cirrhosis","volume":"32","author":"Ai","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"2023120815060343800_hem2023000481C27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12959-023-00449-8","article-title":"Long-term efficacy and safety of anticoagulant for cavernous transformation of the portal vein cirrhotic patient with extrahepatic portal vein obstruction","volume":"21","author":"Zhou","year":"2023","journal-title":"Thromb J"},{"issue":"1","key":"2023120815060343800_hem2023000481C28","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s12325-020-01550-4","article-title":"Anticoagulation favors thrombus recanalization and survival in patients with liver cirrhosis and portal vein thrombosis: results of a meta-analysis","volume":"38","author":"Wang","year":"2021","journal-title":"Adv Ther"},{"issue":"1","key":"2023120815060343800_hem2023000481C29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/MEG.0000000000001237","article-title":"A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis","volume":"31","author":"Rodriguez-Castro","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"2023120815060343800_hem2023000481C30","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jhep.2021.04.029","article-title":"Current knowledge and management of portal vein thrombosis in cirrhosis","volume":"75","author":"Senzolo","year":"2021","journal-title":"J Hepatol"},{"issue":"5","key":"2023120815060343800_hem2023000481C31","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1177\/1060028016631760","article-title":"Anticoagulation in patients with cirrhosis: caught between a rock-liver and a hard place","volume":"50","author":"Ha","year":"2016","journal-title":"Ann Pharmacother"},{"issue":"8","key":"2023120815060343800_hem2023000481C32","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1097\/MEG.0000000000000351","article-title":"Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B","volume":"27","author":"Cui","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"12","key":"2023120815060343800_hem2023000481C33","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1182\/bloodadvances.2022007397","article-title":"Rivaroxaban for the treatment of non-cirrhotic splanchnic vein thrombosis: an interventional prospective cohort study","volume":"6","author":"Ageno","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"2023120815060343800_hem2023000481C34","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1182\/bloodadvances.2019001310","article-title":"The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis","volume":"4","author":"Naymagon","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"2023120815060343800_hem2023000481C35","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200104","article-title":"Rivaroxaban prophylaxis in noncirrhotic portal vein thrombosis","volume":"1","author":"Plessier","year":"2022","journal-title":"NEJM Evid"},{"issue":"1","key":"2023120815060343800_hem2023000481C36","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/hepr.12895","article-title":"Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis","volume":"48","author":"Nagaoki","year":"2018","journal-title":"Hepatol Res"},{"issue":"5","key":"2023120815060343800_hem2023000481C37","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/liv.13285","article-title":"Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis","volume":"37","author":"De Gottardi","year":"2017","journal-title":"Liver Int"},{"issue":"1","key":"2023120815060343800_hem2023000481C38","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.dld.2021.07.039","article-title":"Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist for portal vein thrombosis in cirrhosis: a systematic review and meta-analysis","volume":"54","author":"Koh","year":"2022","journal-title":"Dig Liver Dis"},{"issue":"10","key":"2023120815060343800_hem2023000481C39","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1161\/CIRCULATIONAHA.122.060687","article-title":"Comparative effectiveness and safety of direct oral anticoagulants and warfarin in patients with atrial fibrillation and chronic liver disease: a Nationwide Cohort Study","volume":"147","author":"Lawal","year":"2023","journal-title":"Circulation"},{"issue":"7","key":"2023120815060343800_hem2023000481C40","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1111\/bcp.15693","article-title":"Differences in the location of bleeding with direct oral anticoagulants vs. vitamin K antagonists: a study in the World Health Organization's pharmacovigilance database","volume":"89","author":"Montastruc","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"2023120815060343800_hem2023000481C41","doi-asserted-by":"crossref","first-page":"620217","DOI":"10.1155\/2015\/620217","article-title":"Recurrent thrombotic events after discontinuation of vitamin k antagonist treatment for splanchnic vein thrombosis: a multicenter retrospective cohort study","volume":"2015","author":"Riva","year":"2015","journal-title":"Gastroenterol Res Pract"},{"issue":"6","key":"2023120815060343800_hem2023000481C42","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"issue":"4","key":"2023120815060343800_hem2023000481C43","doi-asserted-by":"crossref","first-page":"682","DOI":"10.4254\/wjh.v14.i4.682","article-title":"Direct oral anticoagulant administration in cirrhotic patients with portal vein thrombosis: what is the evidence?","volume":"14","author":"Biolato","year":"2022","journal-title":"World J Hepatol"},{"issue":"12","key":"2023120815060343800_hem2023000481C44","doi-asserted-by":"crossref","first-page":"e14107","DOI":"10.1111\/ctr.14107","article-title":"Up to 50% of portal vein thrombosis remains undiagnosed until liver transplantation","volume":"34","author":"Bert","year":"2020","journal-title":"Clin Transplant"},{"issue":"1","key":"2023120815060343800_hem2023000481C45","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jhep.2011.12.034","article-title":"Portal vein thrombosis, cirrhosis, and liver transplantation","volume":"57","author":"Francoz","year":"2012","journal-title":"J Hepatol"},{"issue":"2","key":"2023120815060343800_hem2023000481C46","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s11739-023-03206-x","article-title":"Anticoagulation therapy early is safe in portal vein thrombosis patients with acute variceal bleeding: a multi-centric randomized controlled trial","volume":"18","author":"Gao","year":"2023","journal-title":"Intern Emerg Med"},{"issue":"7","key":"2023120815060343800_hem2023000481C47","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/liv.13728","article-title":"Low molecular weight heparin does not increase bleeding and mortality post-endoscopic variceal band ligation in cirrhotic patients","volume":"38","author":"Bianchini","year":"2018","journal-title":"Liver Int"},{"issue":"6","key":"2023120815060343800_hem2023000481C48","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jhep.2008.03.009","article-title":"Thrombocytopenia associated with chronic liver disease","volume":"48","author":"Afdhal","year":"2008","journal-title":"J Hepatol"},{"issue":"3","key":"2023120815060343800_hem2023000481C49","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/ajg.2017.457","article-title":"Platelet count does not predict bleeding in cirrhotic patients: results from the PRO-LIVER Study","volume":"113","author":"Basili","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"2023120815060343800_hem2023000481C50","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/liv.13317","article-title":"Thrombocytopenia in chronic liver disease","volume":"37","author":"Peck-Radosavljevic","year":"2017","journal-title":"Liver Int"},{"issue":"6","key":"2023120815060343800_hem2023000481C51","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/jth.14015","article-title":"Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH","volume":"16","author":"Samuelson Bannow","year":"2018","journal-title":"J Thromb Haemost"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/281\/2175855\/281riva.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/281\/2175855\/281riva.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:09:47Z","timestamp":1702048187000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2023\/1\/281\/506458\/How-to-manage-splanchnic-vein-thrombosis-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,8]]},"published-print":{"date-parts":[[2023,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2023000481","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,8]]},"published":{"date-parts":[[2023,12,8]]}}}